Shun Kaneko

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Matrix stiffness shapes early transcriptional trajectories during hepatic stellate cell activation.

Matrix stiffness shapes early transcriptional trajectories during hepatic stellate cell activation.

Journal: Hepatology international

Published: March 26, 2026

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies.

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies.

Journal: Annals of gastroenterological surgery

Published: October 25, 2025

Primary epithelioid angiosarcoma of the liver.

Primary epithelioid angiosarcoma of the liver.

Journal: Clinical journal of gastroenterology

Published: September 08, 2025

Thermodynamic Perspectives on the Impact of a Second Drug on Amorphous Drug Solubility.

Thermodynamic Perspectives on the Impact of a Second Drug on Amorphous Drug Solubility.

Journal: Molecular pharmaceutics

Published: June 23, 2025

Editorial: Bridging the Gap Between Evidence and Practice in Hepatitis B Virus-Related Hepatocellular Carcinoma Prevention.

Editorial: Bridging the Gap Between Evidence and Practice in Hepatitis B Virus-Related Hepatocellular Carcinoma Prevention.

Journal: Alimentary pharmacology & therapeutics

Published: June 09, 2025

Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases.

Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 09, 2025

Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series.

Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series.

Journal: Clinical journal of gastroenterology

Published: May 02, 2025

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Hepatology international

Published: April 30, 2025

Physical Properties for Novel Cilostazol Co-amorphous; Effect of Preparation Method and Molar Ratio on the Co-amorphous.

Physical Properties for Novel Cilostazol Co-amorphous; Effect of Preparation Method and Molar Ratio on the Co-amorphous.

Journal: Chemical & pharmaceutical bulletin

Published: April 02, 2025

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study.

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study.

Journal: Cancer medicine

Published: March 31, 2025

Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids.

Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids.

Journal: Stem cell reports

Published: December 06, 2024

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

Journal: JHEP reports : innovation in hepatology

Published: August 04, 2024

Showing 1-12 of 84

Last Updated: 09/26/2026